Research brief
A recent study has uncovered a potential issue in screening for Niemann-Pick Disease Type C (NPC), a rare genetic condition. Researchers found that sertraline, a widely used antidepressant, can create biomarker profiles similar to those of NPC, leading to false-positive results. This discovery highlights the need for genetic testing to confirm NPC and raises concerns about how sertraline might affect diagnostic procedures. The study, which analyzed data from several centers, identified sertraline as a common factor in these misleading results.
Key points
- Sertraline can mimic NPC biomarker profiles.
- False positives complicate NPC diagnosis.
- Genetic testing remains crucial for confirmation.
Sertraline and Biomarker Confusion
Researchers reviewed the cases of 15 patients who had false-positive results in NPC biomarker screenings. These patients were referred to French NPC reference labs from 2017 to 2022. Among them, 13 were taking sertraline, which was linked to the altered biomarker profiles. The study suggests that sertraline affects intracellular cholesterol trafficking, a hallmark of NPC, leading to diagnostic confusion.
The Role of Genetic Testing
Despite misleading biomarker profiles, genetic testing for the NPC1 and NPC2 genes is crucial for accurately diagnosing Niemann-Pick Disease Type C. The study emphasizes the importance of genetic analysis to prevent misdiagnosis, especially in patients on sertraline. This ensures patients receive correct diagnoses and appropriate care, avoiding unnecessary stress and treatment delays.
Why it matters
The study's findings have important implications for clinical practice, especially in psychiatric care. Many patients with false-positive biomarker profiles showed unusual psychiatric symptoms, complicating diagnosis. However, one patient exhibited symptoms strongly indicative of NPC after long-term sertraline use. These results highlight the need for further research into sertraline's long-term effects and its potential impact on diagnostic processes.
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
